BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 26905832)

  • 21. Alternative Lengthening of Telomeres in Primary Pancreatic Neuroendocrine Tumors Is Associated with Aggressive Clinical Behavior and Poor Survival.
    Kim JY; Brosnan-Cashman JA; An S; Kim SJ; Song KB; Kim MS; Kim MJ; Hwang DW; Meeker AK; Yu E; Kim SC; Hruban RH; Heaphy CM; Hong SM
    Clin Cancer Res; 2017 Mar; 23(6):1598-1606. PubMed ID: 27663587
    [No Abstract]   [Full Text] [Related]  

  • 22. ATRX loss is an independent predictor of poor survival in pancreatic neuroendocrine tumors.
    Chou A; Itchins M; de Reuver PR; Arena J; Clarkson A; Sheen A; Sioson L; Cheung V; Perren A; Nahm C; Mittal A; Samra JS; Pajic M; Gill AJ
    Hum Pathol; 2018 Dec; 82():249-257. PubMed ID: 30081149
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Proinsulin Expressing Neuroendocrine Tumors of the Pancreas: An Underrecognized Entity.
    Celli R; Tang LH; Cai G; Freedman-Weiss M; Colunga M; Salem RR; Majumdar S; Jain D
    Pancreas; 2019 Jan; 48(1):55-59. PubMed ID: 30451800
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of the tumor microenvironment in predicting postoperative hepatic recurrence of pancreatic neuroendocrine tumors.
    Sato S; Tsuchikawa T; Nakamura T; Sato N; Tamoto E; Okamura K; Shichinohe T; Hirano S
    Oncol Rep; 2014 Dec; 32(6):2753-9. PubMed ID: 25310565
    [TBL] [Abstract][Full Text] [Related]  

  • 25. EPB41L5 is Associated With the Metastatic Potential of Low-grade Pancreatic Neuroendocrine Tumors.
    Saller J; Seydafkan S; Shahid M; Gadara M; Cives M; Eschrich SA; Boulware D; Strosberg JR; Aejaz N; Coppola D
    Cancer Genomics Proteomics; 2019; 16(5):309-318. PubMed ID: 31467225
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Textural analysis on contrast-enhanced CT in pancreatic neuroendocrine neoplasms: association with WHO grade.
    Guo C; Zhuge X; Wang Z; Wang Q; Sun K; Feng Z; Chen X
    Abdom Radiol (NY); 2019 Feb; 44(2):576-585. PubMed ID: 30182253
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Endoplasmic Reticulum Stress in Pancreatic Neuroendocrine Tumors is Linked to Clinicopathological Parameters and Possible Epigenetic Regulations.
    Klieser E; Illig R; Státtner S; Primavesi F; Jáger T; Swierczynski S; Kiesslich T; Kemmerling R; Bollmann C; Di Fazio P; Neureiter D
    Anticancer Res; 2015 Nov; 35(11):6127-36. PubMed ID: 26504039
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Altered PTEN, ATRX, CHGA, CHGB, and TP53 expression are associated with aggressive VHL-associated pancreatic neuroendocrine tumors.
    Weisbrod AB; Zhang L; Jain M; Barak S; Quezado MM; Kebebew E
    Horm Cancer; 2013 Jun; 4(3):165-75. PubMed ID: 23361940
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comprehensive immunohistochemical analysis of histone deacetylases in pancreatic neuroendocrine tumors: HDAC5 as a predictor of poor clinical outcome.
    Klieser E; Urbas R; Stättner S; Primavesi F; Jäger T; Dinnewitzer A; Mayr C; Kiesslich T; Holzmann K; Di Fazio P; Neureiter D; Swierczynski S
    Hum Pathol; 2017 Jul; 65():41-52. PubMed ID: 28235630
    [TBL] [Abstract][Full Text] [Related]  

  • 30. UCHL1 loss alters the cell-cycle in metastatic pancreatic neuroendocrine tumors.
    Finnerty BM; Moore MD; Verma A; Aronova A; Huang S; Edwards DP; Chen Z; Seandel M; Scognamiglio T; Du YN; Elemento O; Zarnegar R; Min IM; Fahey TJ
    Endocr Relat Cancer; 2019 Apr; 26(4):411-423. PubMed ID: 30689542
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic Value of Somatostatin Receptor Subtypes in Pancreatic Neuroendocrine Tumors.
    Song KB; Kim SC; Kim JH; Seo DW; Hong SM; Park KM; Hwang DW; Lee JH; Lee YJ
    Pancreas; 2016 Feb; 45(2):187-92. PubMed ID: 26474434
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cystic Pancreatic Neuroendocrine Tumors Represent a Distinct Clinical Entity with Less Aggressive Biological Behaviors.
    Cheng Y; Wu D; Wang L; Liu H; Xiong Y; Xu J; Hu S; Zhan H
    J Surg Res; 2021 Apr; 260():134-140. PubMed ID: 33340866
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ALCAM (CD166) expression as novel prognostic biomarker for pancreatic neuroendocrine tumor patients.
    Tachezy M; Zander H; Marx AH; Gebauer F; Rawnaq T; Kaifi JT; Sauter G; Izbicki JR; Bockhorn M
    J Surg Res; 2011 Oct; 170(2):226-32. PubMed ID: 21816425
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sporadic nonfunctioning pancreatic neuroendocrine tumors: prognostic significance of incidental diagnosis.
    Birnbaum DJ; Gaujoux S; Cherif R; Dokmak S; Fuks D; Couvelard A; Vullierme MP; Ronot M; Ruszniewski P; Belghiti J; Sauvanet A
    Surgery; 2014 Jan; 155(1):13-21. PubMed ID: 24238123
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Immunohistochemical Evaluation of Solid Pseudopapillary Tumors of the Pancreas and Pancreatic Neuroendocrine Tumors Reveals ERO1Lβ as a New Biomarker.
    Xie J; Zhu Y; Chen H; Shi M; Gu J; Zhang J; Shen B; Deng X; Zhan X; Peng C
    Medicine (Baltimore); 2016 Jan; 95(2):e2509. PubMed ID: 26765469
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ki-67 Index of 5% is Better Than 2% in Stratifying G1 and G2 of the World Health Organization Grading System in Pancreatic Neuroendocrine Tumors.
    Gao SW; Huang CS; Huang XT; Chen LH; Chen W; Cai JP; Yin XY
    Pancreas; 2019 Jul; 48(6):795-798. PubMed ID: 31210659
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical utility of 2-[(18)F] fluoro-2-deoxy-D-glucose positron emission tomography in predicting World Health Organization grade in pancreatic neuroendocrine tumors.
    Tomimaru Y; Eguchi H; Tatsumi M; Kim T; Hama N; Wada H; Kawamoto K; Kobayashi S; Morii E; Mori M; Doki Y; Nagano H
    Surgery; 2015 Feb; 157(2):269-76. PubMed ID: 25311263
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Correlation of computed tomography imaging features and pathological features of 41 patients with pancreatic neuroendocrine tumors.
    Utsumi M; Umeda Y; Takagi K; Takashi K; Nobuoka D; Yoshida R; Shinoura S; Sadamori H; Yagi T; Fujiwara T
    Hepatogastroenterology; 2015; 62(138):441-6. PubMed ID: 25916078
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pathology diagnosis of pancreatic neuroendocrine tumors.
    Kasajima A; Yazdani S; Sasano H
    J Hepatobiliary Pancreat Sci; 2015 Aug; 22(8):586-93. PubMed ID: 25641911
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serotonin, ATRX, and DAXX Expression in Pituitary Adenomas: Markers in the Differential Diagnosis of Neuroendocrine Tumors of the Sellar Region.
    Casar-Borota O; Botling J; Granberg D; Stigare J; Wikström J; Boldt HB; Kristensen BW; Pontén F; Trouillas J
    Am J Surg Pathol; 2017 Sep; 41(9):1238-1246. PubMed ID: 28719461
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.